KR102185237B1 - 항-i형 인터페론 수용체(ifnar) 항체에 대한 고정 투여 계획 - Google Patents

항-i형 인터페론 수용체(ifnar) 항체에 대한 고정 투여 계획 Download PDF

Info

Publication number
KR102185237B1
KR102185237B1 KR1020147037151A KR20147037151A KR102185237B1 KR 102185237 B1 KR102185237 B1 KR 102185237B1 KR 1020147037151 A KR1020147037151 A KR 1020147037151A KR 20147037151 A KR20147037151 A KR 20147037151A KR 102185237 B1 KR102185237 B1 KR 102185237B1
Authority
KR
South Korea
Prior art keywords
delete delete
ifn
leu
type
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147037151A
Other languages
English (en)
Korean (ko)
Other versions
KR102185237B9 (ko
KR20150035825A (ko
Inventor
브랜든 히그스
위홍 야오
빙 왕
로린 로스코스
린다 창
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49758685&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102185237(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Priority to KR1020207033413A priority Critical patent/KR102320059B1/ko
Publication of KR20150035825A publication Critical patent/KR20150035825A/ko
Application granted granted Critical
Publication of KR102185237B1 publication Critical patent/KR102185237B1/ko
Publication of KR102185237B9 publication Critical patent/KR102185237B9/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N7/00—Computing arrangements based on specific mathematical models
    • G06N7/01—Probabilistic graphical models, e.g. probabilistic networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Data Mining & Analysis (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • Primary Health Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Databases & Information Systems (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Probability & Statistics with Applications (AREA)
  • Mathematical Optimization (AREA)
KR1020147037151A 2012-06-13 2013-06-12 항-i형 인터페론 수용체(ifnar) 항체에 대한 고정 투여 계획 Active KR102185237B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020207033413A KR102320059B1 (ko) 2012-06-13 2013-06-12 항-i형 인터페론 수용체(ifnar) 항체에 대한 고정 투여 계획

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261659138P 2012-06-13 2012-06-13
US61/659,138 2012-06-13
PCT/US2013/045327 WO2013188494A1 (en) 2012-06-13 2013-06-12 Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207033413A Division KR102320059B1 (ko) 2012-06-13 2013-06-12 항-i형 인터페론 수용체(ifnar) 항체에 대한 고정 투여 계획

Publications (3)

Publication Number Publication Date
KR20150035825A KR20150035825A (ko) 2015-04-07
KR102185237B1 true KR102185237B1 (ko) 2020-12-02
KR102185237B9 KR102185237B9 (ko) 2021-08-06

Family

ID=49758685

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020147037151A Active KR102185237B1 (ko) 2012-06-13 2013-06-12 항-i형 인터페론 수용체(ifnar) 항체에 대한 고정 투여 계획
KR1020217034200A Ceased KR20210130270A (ko) 2012-06-13 2013-06-12 항-i형 인터페론 수용체(ifnar) 항체에 대한 고정 투여 계획
KR1020207033413A Active KR102320059B1 (ko) 2012-06-13 2013-06-12 항-i형 인터페론 수용체(ifnar) 항체에 대한 고정 투여 계획

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020217034200A Ceased KR20210130270A (ko) 2012-06-13 2013-06-12 항-i형 인터페론 수용체(ifnar) 항체에 대한 고정 투여 계획
KR1020207033413A Active KR102320059B1 (ko) 2012-06-13 2013-06-12 항-i형 인터페론 수용체(ifnar) 항체에 대한 고정 투여 계획

Country Status (9)

Country Link
US (1) US9493570B2 (enExample)
EP (1) EP2861621A4 (enExample)
JP (5) JP2015526391A (enExample)
KR (3) KR102185237B1 (enExample)
CN (3) CN104603152A (enExample)
AU (3) AU2013274389A1 (enExample)
CA (1) CA2876636C (enExample)
HK (1) HK1209758A1 (enExample)
WO (1) WO2013188494A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2643237T3 (es) * 2004-06-21 2017-11-21 E. R. Squibb & Sons, L.L.C. Anticuerpos del receptor 1 de interferón alfa y sus usos
KR100680048B1 (ko) * 2006-01-23 2007-02-08 쌍용자동차 주식회사 자동차 도장용 크레인의 구조
CN108699608A (zh) * 2015-10-09 2018-10-23 基因前沿公司 用于预测和诊断人巨细胞病毒(hCMV)先天性传播的方法和试剂盒
MA45554A (fr) 2016-07-01 2019-05-08 Resolve Therapeutics Llc Fusions de binucléase optimisées.
CN106243226B (zh) * 2016-08-05 2019-02-12 北京智仁美博生物科技有限公司 抗人ifnar1的抗体及其用途
US20200031943A1 (en) 2017-03-21 2020-01-30 Austrianni Gmbh Type 1 interferon receptor antagonists for use in methods of treating tuberculosis and other infectious diseases
CN111315767B (zh) 2017-08-22 2025-03-18 萨纳生物有限责任公司 可溶性干扰素受体及其用途
US11139051B2 (en) 2018-10-02 2021-10-05 Origent Data Sciences, Inc. Systems and methods for designing clinical trials
CA3117102A1 (en) 2018-10-26 2020-04-30 Janssen Biotech, Inc. Type i interferon signatures and methods of use
JP7386877B2 (ja) 2019-01-31 2023-11-27 イミューンセント バイオテクノロジー，インコーポレイテッド 新規の抗ｉｆｎａｒ１抗体
CN111892653A (zh) * 2019-07-03 2020-11-06 长春恒晓生物科技有限责任公司 制备粘病毒抗性蛋白1抗体及建立检测mx1方法
TW202317617A (zh) * 2021-04-23 2023-05-01 瑞典商阿斯特捷利康公司 皮膚紅斑狼瘡之治療
AU2022260544A1 (en) 2021-04-23 2023-11-30 Astrazeneca Ab Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab
SMT202300382T1 (it) * 2021-04-23 2024-01-10 Astrazeneca Ab Regime di dosaggio anti-ifnar1 per iniezione sottocutanea
AU2022317215A1 (en) * 2021-07-27 2024-02-29 Astrazeneca Ab Treatment of lupus
WO2025022280A1 (en) 2023-07-21 2025-01-30 Astrazeneca Ab Treatment of neurodegenerative diseases
GB202402824D0 (en) * 2024-02-28 2024-04-10 Astrazeneca Ab Treatment of chronic kidney disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101666229B1 (ko) * 2008-02-08 2016-10-14 메디뮨 엘엘씨 Ｆｃ 리간드 친화성이 감소된 항-ＩＦＮＡＲ１ 항체

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044406A1 (en) * 2001-03-02 2003-03-06 Christine Dingivan Methods of preventing or treating inflammatory or autoimmune disorders by administering CD2 antagonists in combination with other prophylactic or therapeutic agents
US20040037809A1 (en) * 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
ES2643237T3 (es) * 2004-06-21 2017-11-21 E. R. Squibb & Sons, L.L.C. Anticuerpos del receptor 1 de interferón alfa y sus usos
WO2006128210A1 (en) * 2005-06-03 2006-12-07 John Arthur Notaras A tiller
AU2006259583A1 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
CA2651866C (en) * 2006-05-11 2014-10-28 Universiteit Gent Sialoadhesin-related compositions and methods
CN101594882A (zh) * 2006-12-06 2009-12-02 米迪缪尼有限公司 干扰素α诱导的药代动力学标记物
WO2008070135A2 (en) * 2006-12-06 2008-06-12 Medimmune, Llc. Methods of treating systemic lupus erythematosus
AU2008324800B2 (en) * 2007-11-05 2014-03-27 Astrazeneca Ab Methods of treating scleroderma
US20110287022A1 (en) * 2008-06-20 2011-11-24 Medlmmune, Llc Interferon alpha-induced pharmacodynamic markers
KR20110044905A (ko) * 2008-08-15 2011-05-02 메리맥 파마슈티컬즈, 인크. 치료제에 대한 세포의 반응을 예측하는 방법 및 시스템
SMT201700063T1 (it) 2009-09-03 2017-03-08 Medimmune Llc Diagnosi di interferoni di tipo 1

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101666229B1 (ko) * 2008-02-08 2016-10-14 메디뮨 엘엘씨 Ｆｃ 리간드 친화성이 감소된 항-ＩＦＮＡＲ１ 항체

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J Clin Pharmacol., vol.49, pp.1012~1024(2009)*

Also Published As

Publication number Publication date
KR20210130270A (ko) 2021-10-29
KR102185237B9 (ko) 2021-08-06
CA2876636A1 (en) 2013-12-19
CN111494624A (zh) 2020-08-07
JP7123225B2 (ja) 2022-08-22
KR102320059B1 (ko) 2021-11-01
JP2015526391A (ja) 2015-09-10
AU2020204613A1 (en) 2020-07-30
AU2018206851A1 (en) 2018-08-09
US20150158949A1 (en) 2015-06-11
EP2861621A1 (en) 2015-04-22
AU2020204613B2 (en) 2021-10-07
AU2018206851C1 (en) 2021-11-25
JP6814238B2 (ja) 2021-01-13
CN104603152A (zh) 2015-05-06
KR20200133395A (ko) 2020-11-27
AU2013274389A1 (en) 2015-01-22
JP2018065845A (ja) 2018-04-26
HK1209758A1 (en) 2016-04-08
US9493570B2 (en) 2016-11-15
CA2876636C (en) 2022-09-13
JP2019112429A (ja) 2019-07-11
JP2021167336A (ja) 2021-10-21
KR20150035825A (ko) 2015-04-07
JP2021042208A (ja) 2021-03-18
WO2013188494A1 (en) 2013-12-19
AU2018206851B2 (en) 2020-07-30
EP2861621A4 (en) 2016-01-20
CN108310375A (zh) 2018-07-24

Similar Documents

Publication Publication Date Title
JP7123225B2 (ja) 抗ｉ型インターフェロン受容体（ｉｆｎａｒ）抗体のための固定用量レジメン
JP7854984B2 (ja) 細胞局在シグネチャーおよび免疫療法
KR20180063127A (ko) Il23 경로 바이오마커를 사용한, il23-길항제에 대한 임상 반응의 예측
JP2015504430A (ja) Ｉｌ−７アンタゴニスト及びｐｓａ応答又は非応答対立遺伝子を用いた乾癬性関節炎（ｐｓａ）を治療する方法
MX2013005532A (es) Anticuerpos anti-ligando de quimiocina cc 20 (ccl20) neutralizantes.
KR20140043402A (ko) 인터페론-알파에 대한 항체를 사용하여 전신홍반루푸스, 피부경화증 및 근육염을 치료하는 방법
CN104244979A (zh) 使用il-17拮抗剂治疗强直性脊柱炎的方法
TWI826839B (zh) CD1a抗體及其用途
KR20180096633A (ko) Il23-길항제에 대한 임상적 반응의 예측인자로서의 ccl20
BR112017012515A2 (en) binding members for human c-maf
TWI911277B (zh) 以結合191p4d12蛋白之抗體藥物結合物(adc)治療癌症之方法
HK40034632A (en) Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies
IL301263A (en) BISPECIFIC ANTIBODIES FOR USE IN THE TREATMENT OF NLRC4-GOF INFLAMMASOMAPATHY
Canadian Rheumatology Association Canadian Rheumatology Association Annual Scientific Meeting RBC Convention Centre (and Virtually) Winnipeg, Manitoba, Canada February 28–March 2, 2024
WO2020181080A1 (en) Biomarkers for treatment of cancer
AU2012258819A1 (en) Methods of treating systemic lupus erythematosus, scleroderma, and myositis with an antibody against interferon-alpha

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20141231

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180612

Comment text: Request for Examination of Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20180724

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190705

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20200220

Patent event code: PE09021S02D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20200828

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20201119

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20201125

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20201125

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
J202 Request for trial for correction [limitation]
PJ0202 Trial for correction

Comment text: Request for Trial

Patent event date: 20210623

Patent event code: PJ02022R01D

Comment text: Registration of Establishment

Patent event date: 20201125

Patent event code: PJ02021E01I

Appeal kind category: Correction

Decision date: 20210721

Request date: 20210623

Appeal identifier: 2021105000057

J301 Trial decision

Free format text: TRIAL NUMBER: 2021105000057; TRIAL DECISION FOR CORRECTION REQUESTED 20210623

Effective date: 20210721

PJ1301 Trial decision

Patent event code: PJ13011S03D

Patent event date: 20210721

Comment text: Trial Decision on Correction (Patent, Utility Model)

Appeal kind category: Correction

Request date: 20210623

Decision date: 20210721

Appeal identifier: 2021105000057

G170 Re-publication after modification of scope of protection [patent]
PG1701 Publication of correction

Publication date: 20210806

PR1001 Payment of annual fee

Payment date: 20231017

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20241016

Start annual number: 5

End annual number: 5